What precautions should be taken during high‑dose intravenous immunoglobulin (IVIG) infusion in children, and how can side effects be avoided or minimized?

Precautions During High-Dose IVIG Infusion in Children

Start IVIG infusions slowly at 0.01 mL/kg/min (0.5 mg/kg/min) for the first 30 minutes, then gradually increase to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if well-tolerated, while ensuring adequate hydration before infusion and continuous vital sign monitoring throughout. 1

Pre-Infusion Preparation

Hydration Status

• Ensure patients are not volume-depleted before starting IVIG 1
• Adequate hydration is critical to prevent renal complications and thrombotic events 2, 3
• This is particularly important in high-risk patients

Risk Assessment

Identify high-risk patients who require extra precautions 1:

• Pre-existing renal insufficiency (any degree)
• Diabetes mellitus
• Volume depletion or sepsis
• Patients receiving nephrotoxic medications
• Hypercoagulable conditions or history of thrombosis
• Indwelling central vascular catheters
• Hyperviscosity risk (cryoglobulins, high triglycerides, monoclonal gammopathies)

Baseline Monitoring

• Measure BUN and serum creatinine before initial infusion 1
• Consider baseline blood viscosity assessment in patients at risk for hyperviscosity 1
• Check for IgA deficiency with anti-IgA antibodies (contraindication if present with hypersensitivity history) 1

Infusion Protocol

Rate Titration

The majority of adverse events (81.8%) occur at the 0.04 mL/kg/min infusion rate 4, emphasizing the importance of slow initial rates:

• Begin at 0.01 mL/kg/min (0.5 mg/kg/min) 1
• If tolerated for 30 minutes, gradually increase 1
• Maximum rate: 0.10 mL/kg/min (5 mg/kg/min) 1
• For high-risk patients, use minimum dose and slowest infusion rate practicable 1

Pre-medication

Pre-medication with antihistamines, analgesics, or antipyretics should be considered, as studies show it was used in 75.2% of infusions with good safety outcomes 4

Product Handling

• Do not dilute with IV fluids 1
• Use separate IV line; do not mix with other medications 1
• Do not mix different IVIG brands or formulations 1
• Inspect for particulates; do not use if turbid 1
• Discard partially used vials (no preservative) 1

Monitoring During Infusion

Continuous Surveillance

• Monitor vital signs throughout the entire infusion 1
• Watch for immediate adverse events (occur in 3.5% of infusions) 5
• Most common immediate reactions: fever (1.4%), flushing, chest tightness, blood pressure changes 5, 2

Response to Adverse Events

If adverse reactions occur 1:

1. Slow or stop the infusion immediately
2. Institute symptomatic treatment (analgesics, antihistamines, corticosteroids for severe reactions) 2
3. If symptoms subside promptly, resume at a lower rate comfortable for the patient
4. Discontinue permanently if hypersensitivity or anaphylaxis develops 1

Post-Infusion Monitoring

Delayed Adverse Events

• Delayed-onset adverse events occur in 5.4% of infusions, typically within several hours to 2 days 5
• Most common delayed reaction: headache (2.2% of infusions) 5
• Contact families after infusion completion to monitor for delayed symptoms 5
• Question patients before next infusion about any delayed reactions 5

Ongoing Surveillance

• Periodic monitoring of renal function and urine output, especially in high-risk patients 1
• Monitor for signs of thrombosis (can occur even without known risk factors) 1
• Watch for aseptic meningitis symptoms (headache, neck stiffness, fever) beginning within several hours to 2 days post-infusion 1

Minimizing Side Effects

Evidence-Based Safety Profile

Recent pediatric data demonstrates excellent safety when protocols are followed:

• Overall adverse event rate: 1.2-12.6% of infusions 4, 5, 6
• All adverse events in pediatric studies were mild to moderate; no severe events reported 4, 5
• Patient-level adverse events: 38.8-40.6% of patients experience at least one AE during treatment course 5, 6

Most Common Adverse Events in Children

1. Headache (25.5% of AEs, 2.5% of infusions) 5, 6
2. Fever (17.6% of AEs, 1.8% of infusions) 5, 6
3. Malaise (0.9% of infusions) 5
4. Nausea, fatigue, rash (less common) 5, 6

Key Prevention Strategies

• Slow infusion rates prevent most complications 2, 3
• Adequate hydration prevents renal failure, thrombosis, and aseptic meningitis 2, 3
• Use non-sucrose-containing products to minimize renal risk 1, 2
• Pre-medication reduces immediate reactions 4
• Adverse events are more frequent during initial IVIG exposure 6

Critical Warnings

Serious but Rare Complications

While rare in children, be vigilant for 1:

• Acute renal failure (monitor BUN/creatinine; discontinue if renal function deteriorates)
• Thrombosis (ensure hydration, use minimum effective dose/rate in at-risk patients)
• Aseptic meningitis (resolves within days of discontinuation)
• Anaphylaxis (contraindicated in IgA-deficient patients with anti-IgA antibodies and hypersensitivity history)

Special Considerations

• Avoid live vaccines for 8 months after standard IVIG doses (300-800 mg/kg); extend to 11 months after high-dose (2 g/kg) infusions 7
• Headache is the most prevalent adverse event but rarely requires hospitalization and responds well to acetaminophen 6

The evidence consistently demonstrates that IVIG is safe and well-tolerated in children when administered with appropriate precautions, slow infusion rates, adequate hydration, and continuous monitoring. 4, 5, 6